MAGE-3 peptides presented by HLA class II molecules

US6426217B1 · kind B1 · utility

Assignees

• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
• VRIJE UNIVERSITEIT BRUSSEL · BE

Inventors

• Pascal Chaux · Brussels, BE
• Vincent Stroobant · Brussels, BE
• Thierry Boon-Falleur · Brussels, BE
• Pierre van der Bruggen · Brussels, BE
• Kris Thielemans · Wilrijk, BE
• Jurgen Kurthals · Brussels, BE

Key dates

• Filing date: Oct 27, 2000
• Grant date: Jul 30, 2002
• Expiry date: Oct 27, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.